Table 4.
Logistic multivariate regression to detect independent associations between anti-FOXE3p53-62 Ab levels and clinical and laboratory parameters (continuous and dichotomized) in 75 ACA+ patients
| Variable | B coefficient | Exp (B) | P-valuea | 95% CI |
|---|---|---|---|---|
| Gender | -0.065 | 1.067 | 0.956 | 0.104, 0.914 |
| Age at diagnosis | -0.022 | 0.978 | 0.465 | 0.922, 1.038 |
| Disease duration | 0.039 | 1.040 | 0.661 | 0.943, 1.096 |
| mRss | -0.06 | 0.942 | 0.277 | 0.846, 1.049 |
| ESR | 0.004 | 1.004 | 0.847 | 0.962, 1.049 |
| CRP | -0.052 | 0.949 | 0.749 | 0.689, 1.307 |
| ANA titer | 0.000 | 1.000 | 0.550 | 0.999, 1.002 |
| Anti-Ap1-17 IgG | 0.00 | 1.000 | 0.678 | 0.999, 1.001 |
| Anti-Ap17-30 IgG | 0.108 | 1.114 | 0.035 | 1.007, 1.231 |
| Disease severity score | 0.138 | 1.148 | 0.315 | 0.977, 1.501 |
| Disease activity index | -0.711 | 0.491 | 0.035 | 0.254, 0.950 |
aA P-value >0.05 was not considered statistically significant. ACA, anti-centromere-associated protein antibodies; ANA, anti-nuclear antibodies; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; mRss, modified Rodnan skin score.